Adult acute lymphocytic leukemia (ALL) currently accounts for some 1% of all adult cancers, but nearly 25% of all childhood cancers. Though tremendous advances were achieved in the treatment of pediatric ALL, treatment of this disease in the elderly population has always been challenging, and the degree of molecular diversity is just beginning to be understood. Nevertheless, enormous progress has been made in the understanding of the basic biology of the disease, and novel treatment approaches are currently being investigated with promising results. In addition, one should bear in mind that some specific ALL entities (such as Ph-positive ALL) occupy an essential role as a model for research on cancer pathogenesis and targeted therapeutic interventions in human cancers.
The book 'Adult Acute Lymphocytic Leukemia, Biology and Treatment' edited by AS Advani and HM Lazarus is a multi-authored textbook directed toward the hematologist managing adult ALL, but it may also be useful to the general medical oncologist or internist. The book is structured into 23 different easy to read chapters covering virtually all aspects related to adult ALL. It reviews the recent knowledge and advances in adult ALL pathophysiology and therapy and provides important future research perspectives in this field. The chapters dedicated to the biology, cytogenetics, minimal residual disease, pharmacology and pharmacogenetics of therapies, and molecular therapies are well documented and provide a comprehensive synthesis of invaluable information that is not always easy to find elsewhere in the literature.
From the practical standpoint, chapters dealing with the treatment of Ph þ -ALL and relapsed ALL provide timely and up to date data on novel drugs currently being tested in clinical trials, and which can prove profitable for a wide readership. Although the use of auto-and allo-SCT for adult ALL remains a matter of debate with many conflicting results, the relevant chapters provide a balanced and fair overview. Another intellectually satisfying chapter is the one addressing late consequences of ALL therapy, nicely supporting the fact that immediate survival is no longer the sole concern after treatment of the primary malignancy. Indeed, other aspects, such as complete recovery of health status, normal physical and psychological functioning, normal family and social integration, and good subjective well-being, should be taken into account as part of any treatment strategy.
In the preface, the editors state that 'the future holds great promise and undoubtedly the cure rate in this malignant disorder will continue to increase'. This must be true. Although obviously newer research and clinical studies are rapidly appearing in the literature, for the present this is a welcome robust edition providing specific information and a reference source for hematologists who specialize in ALL management.
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